STAMPEDE otherwise follows a line of randomized trials (e.g., MAST, TAXOMET, IMPROVE) that have failed to prove cancer ...

In a new consensus statement, the European Society of Cardiology has declared vaccinations for common infections to be a ...

By Rishika Sadam HYDERABAD (Reuters) -Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a ...

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...

The stocks listed here each increased their dividend payments by more than 10% recently. When you think of a great dividend ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

The incidence of obesity and diabetes is rising in India, the world’s most populous country, which also ranks among the worst ...

The demand for obesity drugs in India is surging as Eli Lilly and Novo Nordisk compete. A Pakistani startup sends prosthetics ...